Is PAVmed, Inc. overvalued or undervalued?

As of 2 September 2025, the valuation grade for PAVmed, Inc. has moved from fair to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics, particularly with a Price to Book Value of 0.23, an EV to EBIT of -0.43, and an EV to EBITDA of -0.44. In comparison to peers, Delcath Systems, Inc. is considered expensive with a P/E of 68.06, while Neuronetics, Inc. has a risky valuation with a P/E of -5.11, highlighting PAVmed's relatively better positioning.
Despite the attractive valuation, PAVmed has faced significant challenges, as evidenced by its stock performance, which has seen a staggering decline of 98.33% over the past five years compared to a 96.61% increase in the S&P 500. This stark contrast in returns underscores the potential mispricing of the stock, reinforcing the notion that it may be undervalued in the current market environment.